Meeting
2023 ASCO Annual Meeting
Chemotherapy dose density and effect on prognosis for patients with resectable pancreas cancer: A secondary analysis of SWOG S1505.
Authors
Sameer H. Patel
University of Cincinnati Medical Center, Cincinnati, OH
Sameer H. Patel , Sarah Colby , Davendra Sohal , Katherine A Guthrie , Lisa A. Kachnic , E. Gabriela Chiorean , Andrew M. Lowy , Flavio G Rocha , Philip Agop Philip , Syed Ahmad
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer - Local-Regional Disease
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4158)
DOI
10.1200/JCO.2023.41.16_suppl.4158
Abstract #
4158
Poster Bd #
479
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Exploring optimal therapeutic management of STAGE IA PDAC in the era of neoadjuvant chemotherapy.
First Author: Marina Macchini
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Efficacy of sequential perioperative FOLFIRNOX plus gemcitabine nab-paclitaxel for resected pancreatic and periampullary cancers.
First Author: Putao Cen
Poster
2022 ASCO Annual Meeting
Perioperative or adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer: Updated final results of the randomized phase II AIO-NEONAX trial.
First Author: Thomas Jens Ettrich
Poster
2022 ASCO Annual Meeting
Sequential first-line treatment with gemcitabine plus nab-paclitaxel (GA) followed by FOLFIRINOX (FFX) versus FFX alone in patients with metastatic pancreatic cancer (PC): GABRINOX-2 randomized phase 2 trial.
First Author: Fabienne Portales